Rimonabant HCL powder video
ǀ. Raw Rimonabant HCL powder Characters:
|Name:||Rimonabant HCL powder|
Rimonabant HCL (158681-13-1) Introduction
Obesity is a major concern all over the world and is defined as a body mass index of more than 30. It results from accumulation of fat in the body due to excess consumption of fatty foods. In the western countries, obesity is classified as the most common nutritional disorder.
Obesity may lead to other complications and diseases some of which might be fatal. An example of this is atherosclerosis where the arteries are narrowed due to the deposition of fats. This increases the blood pressure as the same volume of blood is prompted to use a narrower passage. This can be life threatening as it may cause a heart attack or stroke.
It is therefore imperative to compliment Rimonabant supplement into your weight management journey along with exercise and diet. This review provides all the information you need to know on Rimonabant supplement for the treatment of obesity.
Chemical Properties of Rimonabant.
Below is the 3-D conformer
What is Rimonabant(158681-13-1)?
Rimonabant is a plant-derived cannabinoid drug that has anorectic and antiobesity properties that helps to suppress your appetite. Though plant-derived cannabinoids have been known for decades, the discovery of Rimonabant drug was a major breakthrough in pharmacology.
It was established that Rimonabant was able to inhibit CB1 receptors. These receptors increased the appetite upon activation by endogenous cannabinoids such as anadamide. This called for more research on this product.
The research ended in an extensive clinical study by Sanofi-Aventi who also marketed it greatly in Europe where it was approved in 2006. It was later approved in Brazil in 2007 and later in other 38 countries. It was the first specific CB1 receptor inverse agonist drug to be approved in the world. Another name for Rimonabant is SR141716 and has been sold in other brand names like Acomplia and Zimulti.
Action of Mechanism of Rimonabant.
- Since Acomplia is a highly selective inhibitor that inhibits the CB1 receptors. These receptors resides in the brain and other peripheral organs namely muscles, liver, adipose tissue and gastro intestinal tract. All these organs play a key role the metabolism of glucose and fat.
- Acomplia also blocks the brain nerves that send the hunger message when one smokes cannabis.
- Acomplia blocks CB1 receptor so that the over activity of endocannabinoid system is reduced. The endocannabinoid system plays a major role in regulating the weight, balancing the energy and also in the metabolism of glucose and fat.
Uses of Rimonabant.
Clinical trials were done on Rimonabant as a potential drug for treating obesity, atherosclerosis, diabetes and smoking cessation. It was established that Rimonabant could promote weight loss in people who were obese though it may trigger anxiety and depression symptoms.
In the Rio-North America clinical trial, 3040 patients were picked at random to receive either one of the two doses of Rimonabant i.e. 5mg or 20mg per day or receive placebo. The patients who received 20mg per day recorded a significant improvement as their weight reduced, their waist circumference decreased, the insulin sensitivity improved and their HDL cholesterol also increased than those on placebo.
- Acomplia was able to help obese patients who also suffered from Diabetes type 2 and had high levels of cholesterol in their blood as well when complemented with their diet and exercise.
- Sanofi also established that Acomplia was able to prevent cardiovascular diseases since the cholesterol was lowered.
- If you are a male patient with a waist circumference of 102cm or a female patient with a waist circumference of 88cm, you may benefit more by using Acomplia.
- If you are struggling with smoking, Acomplia could help you quit. A study done in one year showed 6,500 smokers were motivated to stop smoking.
Several clinical trials were done to examine the safety and the efficacy of Rimonabant as an obesity treatment drug.
These clinical trials explored how blockade of the CB1 receptor was able to cause weight loss and therefore treat obesity. In one particular study, overweight or overweight patients (BMI > 27 kg/m2) who also had dyslipidaemia, and/or high blood pressure, were picked at random and underwent a double-blind treatment using placebo or Rimonabant (5 mg or 20 mg per day). Both groups were also advised to follow a mild low calorie diet. It was established that a dose of 20mg/day of Rimonabant, along with a hypocaloric diet taken over 1 year, realized a significant weight loss, a decreased waist circumference and reduced the risk of developing cardiovascular diseases. After one year, the patients treated with the 20mg of Rimonabant per day also showed better glucose tolerance compared to those on placebo. These benefits were evident even 2 years later while the weight had already stabilized. The study showed that Rimonabant was largely tolerated but had mild and also transient side effects.
Precautions When Taking Rimonabant(158681-13-1).
- Do not take Rimonabant if you have a history of any mental disorder including anxiety and depression.
- Avoid Rimonabant drug if you have had episodes of generalized epilepsy as it may trigger seizures.
- Stay away from Rimonabant if you have ever suffered from any cardiovascular disease.
- This is a prescription only drug and should strictly be taken under your doctor’s instructions.
- Stop taking Rimonabant drug at once if you get an allergic reaction or you experience any side effects.
What to Avoid While Taking Rimonabant.
- Any dietary pills.
- Other medicines whether over-the-counter or prescription.
What to Do if You Miss a Dose.
If you forget to take your medicine, do not try to make up for the missed dose. Either take the missed dose as soon as you remember or just skip and wait for the next dose.
What to Do if You Overdose on Rimonabant.
Call the emergency department as soon as you can.
Rimonabant is the first drug in this category to be developed in the world and acts by selective antagonist of the CB1 receptor. It is able to reduce appetite and subsequently suppress the food intake. It is seen to produce better outcome when given in large doses and when complimented with diet and exercise. It was particularly developed for obese and overweight patients who suffer from other diseases such as type 2 diabetes and had high levels of cholesterol in the blood. It is imperative to have a thorough medical examination prior to taking Rimonabant (CAS 158681-13-1)as it may have adverse side effects.
- National Center for Biotechnology Information, U.S. National Library of Medicine, PubMed.gov. Page 1
- Fong TM, Heymsfield SB (September 2009). “Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions”. Int J Obes (Lond). 33 (9): 947–55
- Gelfand EV, Cannon CP: Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs. 2006 Mar;15(3):307-15.
- Cahill K, Ussher M: Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005353.
Guess your favorite product blog：
|How to take Lorcaserin powder correctly||Clenbuterol HCL Reviews for Women||How to buy Vardenafil hydrochloride raw powder from AASRAW?|
More detail about relevant products,welcome to click here.